Literature DB >> 2832034

Angiotensin converting enzyme inhibitors.

A Breckenridge1.   

Abstract

Mesh：

Substances：

Year:  1988        PMID： 2832034      PMCID： PMC2545245          DOI： 10.1136/bmj.296.6622.618

Source DB:  PubMed          Journal:  Br Med J (Clin Res Ed)        ISSN： 0267-0623


× No keyword cloud information.
  7 in total

1.  History of the development of inhibitors of angiotensin I conversion.

Authors:  S H Ferreira
Journal:  Drugs       Date:  1985       Impact factor: 9.546

2.  Angiotensin-converting enzyme inhibitors in the treatment of hypertension.

Authors:  C I Johnston; L Arnolda; M Hiwatari
Journal:  Drugs       Date:  1984-03       Impact factor: 9.546

3.  Comparison of captopril and enalapril in patients with severe chronic heart failure.

Authors:  M Packer; W H Lee; M Yushak; N Medina
Journal:  N Engl J Med       Date:  1986-10-02       Impact factor: 91.245

Review 4.  Enalapril. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in hypertension and congestive heart failure.

Authors:  P A Todd; R C Heel
Journal:  Drugs       Date:  1986-03       Impact factor: 9.546

Review 5.  The role of vasodilator therapy in the treatment of severe chronic heart failure.

Authors:  M Packer
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 6.  Endocrine mechanisms in congestive cardiac failure. Renin, aldosterone and atrial natriuretic hormone.

Authors:  J H Laragh
Journal:  Drugs       Date:  1986       Impact factor: 9.546

Review 7.  Enalapril: a review of human pharmacology.

Authors:  H J Gomez; V J Cirillo; J D Irvin
Journal:  Drugs       Date:  1985       Impact factor: 9.546
  7 in total
  9 in total

1.  Adverse effects of captopril in hospital outpatients with hypertension.

Authors:  T Walley; P Winstanley; D Roberts; M Grimmer; M Orme; A Breckenridge
Journal:  Postgrad Med J       Date:  1990-02       Impact factor: 2.401

Review 2.  ACE inhibitors and anaesthesia.

Authors:  I McConachie; T E Healy
Journal:  Postgrad Med J       Date:  1989-05       Impact factor: 2.401

3.  Postmarketing surveillance of enalapril 1.

Authors: 
Journal:  BMJ       Date:  1988-11-12

4.  Pharmacokinetics and haemodynamic effects of a single oral dose of the novel ACE inhibitor spirapril in patients with chronic liver disease.

Authors:  S Krähenbühl; P Grass; A Surve; K Kutz; J Reichen
Journal:  Eur J Clin Pharmacol       Date:  1993       Impact factor: 2.953

5.  Effect of renal function on the pharmacokinetics and pharmacodynamics of trandolapril.

Authors:  E G Bevan; G T McInnes; J C Aldigier; J J Conte; J P Grunfeld; S J Harper; B H Meyer; N Pauly; R Wilkinson
Journal:  Br J Clin Pharmacol       Date:  1993-02       Impact factor: 4.335

6.  A comparison of the effects of captopril and enalapril on skin responses to intradermal bradykinin and skin blood flow in the human forearm.

Authors:  T C Li Kam Wa; E D Cooke; P Turner
Journal:  Br J Clin Pharmacol       Date:  1993-01       Impact factor: 4.335

Review 7.  Enalapril. A reappraisal of its pharmacology and therapeutic use in hypertension.

Authors:  P A Todd; K L Goa
Journal:  Drugs       Date:  1992-03       Impact factor: 9.546

8.  Captopril: a free radical scavenger.

Authors:  M Chopra; N Scott; J McMurray; J McLay; A Bridges; W E Smith; J J Belch
Journal:  Br J Clin Pharmacol       Date:  1989-03       Impact factor: 4.335

9.  Enalapril induced severe hyponatremia and altered sensorium in a child.

Authors:  Syed Ahmed Zaki; Swapnil Bhongade; Preeti Shanbag
Journal:  Indian J Pharmacol       Date:  2011-09       Impact factor: 1.200
  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.